Investing.com
Published Dec 19, 2022 09:03AM ET
Jefferies sees Moderna (MRNA) stock 'rebounding back up in 2023', upgrades to Buy
By Senad Karaahmetovic
Moderna (NASDAQ:MRNA) shares are trading almost 3% higher in pre-market Monday after Jefferies analysts upgraded to Buy from Hold.
The analysts also raised the price target to $275 per share (from $170), suggesting an upside of more than 40% from Friday's closing price.
For them, the COVID-19 vaccine story is “old news” with most investors not caring too much about it at this point. The analysts shared 4 reasons why they believe Moderna stock will trade higher in 2023.
“We see stock rebounding back up in 2023, a return of pipeline opportunities and a "story stock" as generalist and HC interest revisits the stock,” the analysts added in an upgrade note.
Moderna stock price is down almost 24% year-to-date (YTD).
Written By: Investing.com
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.